ClinicalTrials.Veeva

Menu

Sublingual Misoprostol Versus No Cervical Priming Before Hysteroscopic Resection of Symptomatic Uterine Niches

B

Benha University

Status

Completed

Conditions

Cesarean Section Complications
Scar Niche
Abnormal Uterine Bleeding

Treatments

Diagnostic Test: Saline-infusion Sonohysterography
Drug: Misoprostol 200mcg Tab
Other: Placebo tab
Procedure: Hysteroscopic resection of uterine niche

Study type

Interventional

Funder types

Other

Identifiers

NCT07271056
RC11-2-2025

Details and patient eligibility

About

The purpose of the study is to evaluated whether preoperative sublingual misoprostol can enhance the effectiveness and safety of niche resection in patients with symptomatic uterine niche.

Full description

After eligibility and consenting, Participants with symptomatic uterine niche were randomized (1:1) to sublingual misoprostol or placebo. Baseline demographic and clinical variables (age, BMI, number of prior cesarean section, number of days of postmenstrual spotting, pelvic pain, dysmenorrhea, dyspareunia, and dysuria) were collected. Symptom severity was assessed using a visual analogue scale (VAS, 1-10). Baseline niche characteristics (residual myometrial thickness, depth, length, and width) were measured by saline infusion sonohysterography. The misoprostol group received 200 µg sublingual misoprostol tablet two hours before surgery; controls received identical placebo tablets. Hysteroscopic resection of uterine niche was performed around cycle day 10 under spinal or general anesthesia using a 9-mm resectoscope with monopolar energy and 3.5% sorbitol for uterine distension. Misoprostol-related adverse events (cramping, fever, GI upset) were recorded preoperatively by a trained nurse. The Sanders and Murji technique was adapted as follow: (1) anatomical orientation, (2) cephalic rim resection, (3) caudal rim resection, and (4) rollerball ablation of the niche base . Intraoperative data (duration, need for dilators, intra- and postoperative complications). At 3 months postoperatively, participants were reassessed for reduction in number of days of postmenstrual spotting, changes in pelvic pain, dysmenorrhea, dyspareunia, and dysuria (VAS scores), participants satisfaction (satisfied/very satisfied vs. dissatisfied/neutral), , and sonohysterographic niche measurements (RMT, depth, length, width).

The participants, hysteroscopist, outcome assessors, and the investigator were blinded for the assignment of the participants to either groups.

Enrollment

56 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ≥1 previous cesarean section
  • Post cesarean section uterine niche confirmed by saline infusion sonohysterography (niche depth ≥2 mm)
  • Residual myometrial thickness ≥2.5 mm as confirmed by saline infusion sonohysterography
  • Regular cycles
  • Abnormal uterine bleeding for ≥3 consecutive cycles
  • Post menstrual spotting or brownish discharge ≥2 days
  • Total monthly bleeding duration >7 days

Exclusion criteria

  • Irregular cycles
  • Amenorrhea
  • Abnormal cervical cytology
  • Acute or chronic cervicitis
  • Pelvic inflammatory disease
  • Endometrial polyps
  • Uterine fibroids
  • Contraindications to spinal or general anesthesia
  • Refusal to participate

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

56 participants in 2 patient groups, including a placebo group

Misoprostol group
Active Comparator group
Description:
Misoprostol group received 200 µg sublingual misoprostol tablet two hours before hysteroscopic resection of uterine niche.
Treatment:
Procedure: Hysteroscopic resection of uterine niche
Drug: Misoprostol 200mcg Tab
Diagnostic Test: Saline-infusion Sonohysterography
Placebo group
Placebo Comparator group
Description:
Placebo group received sublingual identical placebo tablet two hours before hysteroscopic resection of uterine niche.
Treatment:
Procedure: Hysteroscopic resection of uterine niche
Other: Placebo tab
Diagnostic Test: Saline-infusion Sonohysterography

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems